سعر جليبنكلاميد 5 مجم 10 أقراص 2022

Glibenclamide (glyburide) 5 mg tablets, 10s, EIPICO, BP 2004 listing in Egyptian directories.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when metformin is not appropriate or as add-on therapy (sulfonylurea glibenclamide (glyburide)).Population: Adults with type 2 diabetesDailyMed (U.S. National Library of Medicine)

• Common: hypoglycaemia, weight gain, gastrointestinal upset; uncommon: skin reactions; rare: blood dyscrasias, hepatic dysfunction (class effects of sulfonylureas).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to glibenclamide (glyburide) or other sulfonylureas/sulfonamides; type 1 diabetes; diabetic ketoacidosis; severe renal or hepatic impairment (per sulfonylurea labeling).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypoglycaemia risk is the principal warning for sulfonylureas — higher in elderly, renal/hepatic impairment, irregular meals, and with alcohol or interacting drugs; educate patients on recognition and treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Insulin / other insulin secretagogues / alcohol / CYP2C9 modulators (drug-dependent)MajorAdditive hypoglycaemia with insulin or secretagogues and alcohol; some sulfonylureas interact via CYP2C9 — monitor glucose closely.DailyMed (U.S. National Library of Medicine)

• glibenclamide (glyburide) sulfonylureas are generally not preferred in pregnancy; insulin is usually recommended. Follow local obstetric guidance.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Excretion into breast milk and risk to the infant are incompletely characterized for many sulfonylureas; avoid or use alternative therapy during breastfeeding unless a local label permits.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Glibenclamide: Stimulates insulin release from pancreatic beta cells via SUR1/KATP channel closure.